Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 13 - Drugs for disorders of the urinary system
Patents for A61P 13 - Drugs for disorders of the urinary system (56,135)
12/2003
12/31/2003WO2004001047A1 Novel promoter
12/31/2003WO2004001004A2 Membrane associated tumor endothelium markers
12/31/2003WO2004000846A1 Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors
12/31/2003WO2004000841A1 Hetero-bicyclic compounds
12/31/2003WO2004000840A2 Quinuclidine derivatives and pharmaceutical compositions containing the same
12/31/2003WO2004000839A1 Thiazole derivatives as phosphodiesterase iv inhibitors
12/31/2003WO2004000833A1 Processes for preparing substituted pyrimidines and pyrimidine derivatives as inhibitors of protein kinase
12/31/2003WO2004000830A1 Novel compounds, their use and preparation
12/31/2003WO2004000817A2 Benzimidazole compounds and their use as estrogen agonists/antagonists
12/31/2003WO2004000813A1 Phenoxypyridine derivative or salt thereof
12/31/2003WO2004000807A1 Cannabinoid receptor agonists
12/31/2003WO2004000368A1 Pharmaceutical use of nitric oxide, heme oxygenase-1 and products of heme degradation
12/31/2003WO2004000361A1 Metastable pharmaceutical compositions
12/31/2003WO2004000333A1 Novel complexes of fatty acid esters of polyhydroxyalkanes and pyridine carboxy derivatives
12/31/2003WO2004000294A1 Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance
12/31/2003WO2004000237A2 Enhancing treatment of mdr cancer with adenosine a3 antagonists
12/31/2003WO2004000225A2 Use of thio-oxindole derivatives in treatment of hormone-related conditions
12/31/2003WO2003072704A3 RNA INTERFERENCE MEDIATED INHIBITION OF PLATELET DERIVED GROWTH FACTOR (PDGF) AND PLATELET DERIVED GROWTH FACTOR RECEPTOR (PDGFR) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
12/31/2003WO2003068811A3 Cytotoxic t-cell epitopes from chlamydia
12/31/2003WO2003061573A3 Methods and compositions for treating urological disorders using 1435, 559, 34021, 44099, 25278, 641, 260, 55089, 21407, 42032, 46656, 62553, 302, 323, 12303, 985, 13237, 13601, 18926, 318, 2058 or 6351 mo
12/31/2003WO2003059269A3 Acridone inhibitors of impdh enzyme
12/31/2003WO2003055912A3 Secreted proteins
12/31/2003WO2003010286A9 Nucleic acids, polypeptides, and methods for modulating apoptosis
12/31/2003WO2003006492A3 Biologically active peptides
12/31/2003WO2002070562A3 Nuclear hormone receptor ligand binding domain
12/31/2003WO2002060378A3 Substituted aryl compounds as cyclooxygenase-2 selective inhibitors, compositions and methods of use
12/31/2003WO2002047708A3 Selective cox-2 inhibition from edible plant extracts
12/31/2003WO2002040671A3 Immunoglobulin superfamily proteins
12/31/2003WO2001006984A3 Small molecules useful in the treatment of inflammatory disease
12/31/2003CN1463732A Kidney tonifying capsule
12/31/2003CN1463715A Nitrel Chinese medicine herb prescription
12/31/2003CN1463714A Traditional Chinese medicine prescription for treating uremia
12/31/2003CN1463610A Process for making liquorice tea
12/31/2003CN1132602C Full-natural medicine for treating calculus
12/31/2003CN1132601C Medicine for treating urinary tract calculus
12/31/2003CA2490684A1 Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance
12/31/2003CA2490526A1 Hetero-bicyclic compounds
12/31/2003CA2490392A1 Pharmaceutical use of nitric oxide, heme oxygenase-1 and products of heme degradation
12/31/2003CA2490082A1 Quinuclidine derivatives and pharmaceutical compositions containing the same
12/31/2003CA2490057A1 Metastable pharmaceutical compositions
12/31/2003CA2489813A1 Use of thio-oxindole derivatives in treatment of hormone-related conditions
12/31/2003CA2487718A1 Arylamine substituted bicyclic heteroaromatic compounds as p38 kinase inhibitors
12/31/2003CA2487346A1 Cannabinoid receptor agonists
12/31/2003CA2487266A1 Benzimidazole compounds and their use as estrogen agonists/antagonists
12/31/2003CA2485537A1 Novel compounds, their use and preparation
12/31/2003CA2480892A1 Novel promoter
12/31/2003CA2464539A1 Enhancing treatment of mdr cancer with adenosine a3 antagonists
12/31/2003CA2445515A1 Transcription factor modulating compounds and methods of use thereof
12/30/2003US6670473 Inhibitors of nitric oxide synthase (nos)
12/30/2003US6670392 Administering vitamin e and selenium, or compound thereof
12/30/2003US6670389 Laulimalide derivatives
12/30/2003US6670382 Hydroxyformamidine derivatives and medicines containing the same
12/30/2003US6670366 Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction
12/30/2003US6670364 Antagonists of MCP-1 function and methods of use thereof
12/30/2003US6670359 Such as (S)-N-(5-(4-Methylpiperazin-1-yl)-3,4-dihydro-2H-1-benzopyran-3-yl)-4 -morpholinobenzamide for treatment of mood/anxiety/eating disorders
12/30/2003US6670341 Phosphocholine moiety covalently conjugated with one or more antiviral agents (e.g. nucleoside analogue, protease inhibitor, etc.) to a lipid backbone
12/30/2003US6670136 Peptide for use in the treatment of inflammation defects
12/30/2003US6669966 Topically applying oxides of bismuth, cobalt, copper, iron, manganese or praseodymium, as ointments or on bandages to improve neovascularization of injuries or skin disorders
12/30/2003CA2293621C 4-aminopyrrole(3,2-d) pyrimidines as neuropeptide y receptor antagonists
12/30/2003CA2288977C Use of diphosphonic acids or the physiologically acceptable salts or esters thereof in the preventive treatment of after-effects resulting from enlargement or replacement of the bladder
12/25/2003WO2003105846A1 2-ureido-6-heteroaryl-3h-benzoimidazole-4-carboxylic acid derivatives and related compounds as gyrase and/or topoisomerase iv inhibitors for the treatment of bacterial infections
12/25/2003US20030236412 Cyclic AMP-specific phosphodiesterase inhibitors
12/25/2003US20030236389 Proteins, polynucleotides encoding them and methods of using the same
12/25/2003US20030236309 Novel formate salt of O-desmethyl-venlafaxine
12/25/2003US20030236286 Central nervous system disorders; cardiovascular disorders; antiischemic agents; psychological disorders
12/25/2003US20030236281 Quinoline derivatives(2)
12/25/2003US20030236280 Aminotetralin-derived urea modulators of vanilloid VR1 receptor
12/25/2003US20030236272 Method and composition for treatment of diabetes, hypertension, chronic heart failure and fluid retentive states
12/25/2003US20030236267 Benzimidazole derivatives
12/25/2003US20030236263 Chemical compounds
12/25/2003US20030236258 Heterocyclo-alkylsulfonyl pyrazole derivatives as anti-inflammatory/analgesic agents
12/25/2003US20030236252 Brain disorders, cardiovascular disorders, strokes, Parkinson's disease
12/25/2003US20030236213 Compounds useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders
12/25/2003US20030236212 Compounds useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders
12/25/2003US20030235900 Anticancer agents
12/25/2003US20030235588 Thioredoxin (TRX); administering histone deacetylase inhibitors such as trichostatin A; for treating inflammation
12/25/2003US20030235585 Methods of treating disorders in which TFN alpha activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor alpha
12/25/2003US20030235584 Method for preparing anti-MIF antibodies
12/24/2003WO2003106707A1 Method for detecting increased susceptibility to tumours
12/24/2003WO2003106660A2 Immunomodulation and effect on cell processes relating to serotonin family receptors and the blood-brain barrier
12/24/2003WO2003106462A1 Benzofused heteroaryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use
12/24/2003WO2003106456A2 New compounds
12/24/2003WO2003106446A1 Non-peptide gnrh agents, pharmaceutical compositions and methods for their use
12/24/2003WO2003106444A1 N,n-disubstituted diazocycloalkanes useful for the treatment of cns disorders due to serotonergic dysfunction
12/24/2003WO2003106443A1 1-phenylalkyl-piperazines
12/24/2003WO2003106441A1 Pharmaceutical salts of reboxetine
12/24/2003WO2003106425A2 Phenyl- and pyridyl-diazaheterocycles having a tnf-modulating activity
12/24/2003WO2003106423A1 Cyclic amine and medicinal composition containing the same
12/24/2003WO2003106421A2 Phenylalkylamines and pyridylalkylamines
12/24/2003WO2003106418A1 Indole, indazole, and benzazole derivative
12/24/2003WO2003106410A1 Fluorinated cycloalkyl-derivatised benzoylguanidines and their use as a medicament
12/24/2003WO2003106403A1 Carboxamides derivatives
12/24/2003WO2003106402A1 2-naphtamide derivatives
12/24/2003WO2003106401A1 N-bridged selective androgen receptor modulators and methods of use thereof
12/24/2003WO2003106381A2 Human adam-10 inhibitors
12/24/2003WO2003105893A2 Probiotic therapies
12/24/2003WO2003105776A2 ANALOGUES OF LIPID MEDIATORS DERIVED FROM OMEGA-3 PUFAs AND METHODS OF USE
12/24/2003WO2003105771A2 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)pyrrolidine-3-carboxylates as edg receptor agonists
12/24/2003WO2003105666A2 Method of treating ischemia reperfusion injury using adenosine receptor antagonists
12/24/2003WO2003084940B1 Thiazolidine-4-carbonitriles and analogues and their use as dipeptidyl-peptidas inhibitors
1 ... 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 ... 562